G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study
Active, not recruiting · Not applicable · NCT04754087
Conditions: Total Hip Arthroplasty, Degenerative Joint Disease of Hip, Avascular Necrosis of Hip, Rheumatoid Arthritis of Hip, Osteoarthritis, Hip, Osteoarthritis of Hip, Fractures, Hip, Fracture of Hip
At a glance
- Research payments reported, 2025
- $7,954
- U.S. investigators named
- 1
- Sites paid
- 2
- Planned or actual enrollment
- 300
About the trial
- Sponsor
- Zimmer Biomet
- Tested
- Vivacit-E and Longevity (HXLPE) Liners (device)
- Dates
- Started 2021-07-07; completion 2033-12-31
- Results posted
- Not yet
The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Acetabular Shells when used with the Vivacit-E and Longevity HXLPE liners and instrumentation in primary and revision total hip arthroplasty.
From ClinicalTrials.gov, last updated 2026-07-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Zimmer Biomet Holdings, Inc. reported $7,954 in research payments for this study in 2025 (3 payments).
Products named: G7
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Donald B Slocum Research and Edu Found $5,864
- Wcg Irb $2,090
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.